• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

MYCN介导的人类神经母细胞瘤中多药耐药相关蛋白1(MRP1)启动子的调控

MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma.

作者信息

Manohar Chitra F, Bray James A, Salwen Helen R, Madafiglio Janice, Cheng Andy, Flemming Claudia, Marshall Glenn M, Norris Murray D, Haber Michelle, Cohn Susan L

机构信息

The Robert H Lurie Comprehensive Cancer Center, Northwestern University's Feinberg School of Medicine, Chicago, IL, USA.

出版信息

Oncogene. 2004 Jan 22;23(3):753-62. doi: 10.1038/sj.onc.1207151.

DOI:10.1038/sj.onc.1207151
PMID:14737110
Abstract

In the childhood cancer neuroblastoma (NB), the level of expression of the multidrug resistance-associated protein (MRP1) gene is strongly correlated with expression of the MYCN oncogene in primary NB tumors, suggesting that MRP1 may be a target for MYCN-mediated gene regulation. In this study, we show that MYCN induction in human NB cells results in increased MRP1 mRNA and protein levels, which in turn is accompanied by increased drug resistance and enhanced MRP1-mediated drug efflux. Furthermore, luciferase activity from MRP1 promoter/luciferase gene reporter constructs was significantly increased in NB cells with exogenous overexpression of MYCN, whereas activity was decreased in NB cells stably transfected with MYCN-antisense vectors. Decreased luciferase activity was observed with promoter constructs that lacked one or two E-box sequences or had E-box double point mutations, while a truncated MRP1 promoter lacking all three E-boxes exhibited only basal levels of activity. Specific electrophoretic mobility shifts of MRP1 E-box sequences were detected with nuclear extracts from NB cells with MYCN overexpression, and complex formation was inhibited with the addition of antibodies directed against MYCN or MYC. These findings indicate that by interacting with E-box elements within the promoter, MYCN can upregulate MRP1 expression and modulate drug resistance in NB.

摘要

在儿童癌症神经母细胞瘤(NB)中,多药耐药相关蛋白(MRP1)基因的表达水平与原发性NB肿瘤中MYCN癌基因的表达密切相关,这表明MRP1可能是MYCN介导的基因调控的一个靶点。在本研究中,我们发现人NB细胞中MYCN的诱导导致MRP1 mRNA和蛋白水平升高,进而伴随着耐药性增加和MRP1介导的药物外排增强。此外,在MYCN外源性过表达的NB细胞中,MRP1启动子/荧光素酶基因报告构建体的荧光素酶活性显著增加,而在稳定转染MYCN反义载体的NB细胞中活性降低。对于缺少一个或两个E-box序列或具有E-box双点突变的启动子构建体,观察到荧光素酶活性降低,而缺少所有三个E-box的截短MRP1启动子仅表现出基础水平的活性。在MYCN过表达的NB细胞核提取物中检测到MRP1 E-box序列的特异性电泳迁移率变化,并且通过添加针对MYCN或MYC的抗体抑制了复合物的形成。这些发现表明,通过与启动子内的E-box元件相互作用,MYCN可以上调MRP1表达并调节NB中的耐药性。

相似文献

1
MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma.MYCN介导的人类神经母细胞瘤中多药耐药相关蛋白1(MRP1)启动子的调控
Oncogene. 2004 Jan 22;23(3):753-62. doi: 10.1038/sj.onc.1207151.
2
MYCN enhances P-gp/MDR1 gene expression in the human metastatic neuroblastoma IGR-N-91 model.MYCN在人转移性神经母细胞瘤IGR-N-91模型中增强P-糖蛋白/多药耐药基因1(P-gp/MDR1)的表达。
Am J Pathol. 2003 Jul;163(1):321-31. doi: 10.1016/S0002-9440(10)63656-5.
3
Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bbeta and TSLC1 in neuroblastoma.BMI1 是 MYCN 的一个靶基因,通过抑制神经母细胞瘤中的 KIF1Bβ和 TSLC1 来调节肿瘤发生。
Oncogene. 2010 May 6;29(18):2681-90. doi: 10.1038/onc.2010.22. Epub 2010 Mar 1.
4
Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features.在具有不良生物学特征的神经母细胞瘤中,肿瘤抑制因子BIN1的一种与MYCN相互作用的亚型表达降低。
Clin Cancer Res. 2003 Aug 15;9(9):3345-55.
5
MYCN-regulated miRNA-92 inhibits secretion of the tumor suppressor DICKKOPF-3 (DKK3) in neuroblastoma.MYCN 调控的 microRNA-92 抑制神经母细胞瘤中肿瘤抑制因子 DICKKOPF-3(DKK3)的分泌。
Carcinogenesis. 2011 Jul;32(7):1005-12. doi: 10.1093/carcin/bgr073. Epub 2011 May 13.
6
CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression.CTCF与非编码RNA MYCNOS协同作用,通过促进MYCN表达来推动神经母细胞瘤进展。
Oncogene. 2016 Jul 7;35(27):3565-76. doi: 10.1038/onc.2015.422. Epub 2015 Nov 9.
7
Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma.微小染色体维持蛋白MCM7是神经母细胞瘤中MYCN转录因子的直接靶点。
Cancer Res. 2002 Feb 15;62(4):1123-8.
8
Targeted MYCN expression affects cytotoxic potential of chemotherapeutic drugs in neuroblastoma cells.靶向MYCN表达影响神经母细胞瘤细胞中化疗药物的细胞毒性潜力。
Cancer Lett. 2007 May 18;250(1):17-24. doi: 10.1016/j.canlet.2006.09.010. Epub 2006 Dec 4.
9
Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma.在一项大型原发性神经母细胞瘤前瞻性研究中,高水平多药耐药相关蛋白1(MRP1)表达与不良临床预后的关联。
J Clin Oncol. 2006 Apr 1;24(10):1546-53. doi: 10.1200/JCO.2005.01.6196.
10
Importance of Sp1 consensus motifs in the MYCN promoter.Sp1共有基序在MYCN启动子中的重要性。
Surgery. 2002 Aug;132(2):232-8. doi: 10.1067/msy.2002.125387.

引用本文的文献

1
Targeting the MYCN-MDM2 pathways for cancer therapy: Are they druggable?靶向MYCN-MDM2通路进行癌症治疗:它们是否具有可药用性?
Genes Dis. 2023 Oct 27;12(2):101156. doi: 10.1016/j.gendis.2023.101156. eCollection 2025 Mar.
2
ABCC1 Is a ΔNp63 Target Gene Overexpressed in Squamous Cell Carcinoma.ABCC1 是ΔNp63 的靶基因,在鳞状细胞癌中过表达。
Int J Mol Sci. 2024 Aug 10;25(16):8741. doi: 10.3390/ijms25168741.
3
Extracellular Vesicles and Cancer Multidrug Resistance: Undesirable Intercellular Messengers?细胞外囊泡与癌症多药耐药性:不良的细胞间信使?
Life (Basel). 2023 Jul 27;13(8):1633. doi: 10.3390/life13081633.
4
P-glycoprotein: new insights into structure, physiological function, regulation and alterations in disease.P-糖蛋白:关于其结构、生理功能、调节及疾病中的改变的新见解
Heliyon. 2022 Jun 22;8(6):e09777. doi: 10.1016/j.heliyon.2022.e09777. eCollection 2022 Jun.
5
MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma.MYCN 驱动的脂肪酸摄取是神经母细胞瘤的代谢脆弱性。
Nat Commun. 2022 Jun 28;13(1):3728. doi: 10.1038/s41467-022-31331-2.
6
Recent advances in the developmental origin of neuroblastoma: an overview.神经母细胞瘤发生发展的最新研究进展:综述
J Exp Clin Cancer Res. 2022 Mar 11;41(1):92. doi: 10.1186/s13046-022-02281-w.
7
A Focus on Regulatory Networks Linking MicroRNAs, Transcription Factors and Target Genes in Neuroblastoma.关注神经母细胞瘤中连接微小RNA、转录因子和靶基因的调控网络。
Cancers (Basel). 2021 Nov 3;13(21):5528. doi: 10.3390/cancers13215528.
8
Excellent Early Outcomes of Combined Chemotherapy With Arsenic Trioxide for Stage 4/M Neuroblastoma in Children: A Multicenter Nonrandomized Controlled Trial.砷剂联合化疗治疗儿童 4 期/M 神经母细胞瘤的优异早期结果:一项多中心非随机对照试验。
Oncol Res. 2021 Sep 7;28(7):791-800. doi: 10.3727/096504021X16184815905096. Epub 2021 Apr 15.
9
The Combination of the M2 Muscarinic Receptor Agonist and Chemotherapy Affects Drug Resistance in Neuroblastoma Cells.M2 毒蕈碱型乙酰胆碱受体激动剂与化疗联合作用影响神经母细胞瘤细胞的耐药性。
Int J Mol Sci. 2020 Nov 10;21(22):8433. doi: 10.3390/ijms21228433.
10
Pharmacodynamic mechanisms of anti-inflammatory drugs on the chemosensitization of multidrug-resistant cancers and the pharmacogenetics effectiveness.抗炎药物对多药耐药性癌症化疗增敏的药效学机制和药物遗传学效果。
Inflammopharmacology. 2021 Feb;29(1):49-74. doi: 10.1007/s10787-020-00765-9. Epub 2020 Oct 17.